February OTAT Town Hall Will Focus on Gene Therapy Products for Rare Diseases

January 10, 2023

The Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) will host a virtual town hall Feb. 7 to answer stakeholder questions related to the clinical development of gene therapy products for rare diseases (excluding hematology/oncology products).

The virtual town hall will take place via Zoom. Registration is required. Attendees may submit questions for the event upon registration and during the live event. FDA is unable to answer questions regarding specific investigational products or drug applications during the event.